Acceptance of COVID-19 vaccine among sub-Saharan Africans (SSA): a comparative study of residents and diasporan dwellers.


Journal

BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562

Informations de publication

Date de publication:
28 01 2023
Historique:
received: 05 04 2022
accepted: 23 01 2023
entrez: 28 1 2023
pubmed: 29 1 2023
medline: 1 2 2023
Statut: epublish

Résumé

The COVID-19 vaccines are being rolled out across all the sub-Saharan Africa (SSA) countries, with countries setting targets for achieving full vaccination rates. The aim of this study was to compare the uptake of, resistance and hesitancy to the COVID-19 vaccine between SSA locally residents and in the diasporan dwellers. This was a cross-sectional study conducted using a web and paper-based questionnaire to obtain relevant information on COVID-19 vaccine acceptance. The survey items included questions on demography, uptake and planned acceptance or non-acceptance of the COVID-19 vaccines among SSAs. Multinomial logistic regression was used to determine probabilities of outcomes for factors associated with COVID-19 vaccination resistance and hesitancy among SSA respondents residing within and outside Africa. Uptake of COVID-19 vaccines varied among the local (14.2%) and diasporan (25.3%) dwellers. There were more locals (68.1%) who were resistant to COVID-19 vaccine. Participants' sex [adjusted relative risk (ARR) = 0.73, 95% CI: 0.58 - 0.93], education [primary/less: ARR = 0.22, CI:0.12 - 0.40, and bachelor's degree: ARR = 0.58, CI: 0.43 - 0.77]), occupation [ARR = 0.32, CI: 0.25-0.40] and working status [ARR = 1.40, CI: 1.06-1.84] were associated with COVID-19 vaccine resistance among locals. Similar proportion of local and diasporan dwellers (~ 18% each) were hesitant to COVID-19 vaccine, and this was higher among health care workers [ARR = 0.25, CI: 0.10 - 0.62 and ARR = 0.24, CI:0.18-0.32, diaspora and locals respectively]. After adjusting for the potential confounders, local residents aged 29-38 years [ARR = 1.89, CI: 1.26-2.84] and lived in East Africa [ARR = 4.64, CI: 1.84-11.70] were more likely to report vaccine hesitancy. Knowledge of COVID vaccines was associated with hesitancy among local and diasporan dwellers, but perception was associated with vaccine resistance [ARR = 0.86,CI: 0.82 - 0.90] and hesitancy [ARR = 0.85, CI: 0.80 - 0.90], only among the local residents. Differences exist in the factors that influence COVID-19 vaccine acceptance between local SSA residents and thediasporan dwellers. Knowledge about COVID-19 vaccines affects the uptake, resistance, and hesitancy to the COVID-19 vaccine. Information campaigns focusing on the efficacy and safety of vaccines could lead to improved acceptance of COVID-19 vaccines.

Sections du résumé

BACKGROUND
The COVID-19 vaccines are being rolled out across all the sub-Saharan Africa (SSA) countries, with countries setting targets for achieving full vaccination rates. The aim of this study was to compare the uptake of, resistance and hesitancy to the COVID-19 vaccine between SSA locally residents and in the diasporan dwellers.
METHODS
This was a cross-sectional study conducted using a web and paper-based questionnaire to obtain relevant information on COVID-19 vaccine acceptance. The survey items included questions on demography, uptake and planned acceptance or non-acceptance of the COVID-19 vaccines among SSAs. Multinomial logistic regression was used to determine probabilities of outcomes for factors associated with COVID-19 vaccination resistance and hesitancy among SSA respondents residing within and outside Africa.
RESULTS
Uptake of COVID-19 vaccines varied among the local (14.2%) and diasporan (25.3%) dwellers. There were more locals (68.1%) who were resistant to COVID-19 vaccine. Participants' sex [adjusted relative risk (ARR) = 0.73, 95% CI: 0.58 - 0.93], education [primary/less: ARR = 0.22, CI:0.12 - 0.40, and bachelor's degree: ARR = 0.58, CI: 0.43 - 0.77]), occupation [ARR = 0.32, CI: 0.25-0.40] and working status [ARR = 1.40, CI: 1.06-1.84] were associated with COVID-19 vaccine resistance among locals. Similar proportion of local and diasporan dwellers (~ 18% each) were hesitant to COVID-19 vaccine, and this was higher among health care workers [ARR = 0.25, CI: 0.10 - 0.62 and ARR = 0.24, CI:0.18-0.32, diaspora and locals respectively]. After adjusting for the potential confounders, local residents aged 29-38 years [ARR = 1.89, CI: 1.26-2.84] and lived in East Africa [ARR = 4.64, CI: 1.84-11.70] were more likely to report vaccine hesitancy. Knowledge of COVID vaccines was associated with hesitancy among local and diasporan dwellers, but perception was associated with vaccine resistance [ARR = 0.86,CI: 0.82 - 0.90] and hesitancy [ARR = 0.85, CI: 0.80 - 0.90], only among the local residents.
CONCLUSIONS
Differences exist in the factors that influence COVID-19 vaccine acceptance between local SSA residents and thediasporan dwellers. Knowledge about COVID-19 vaccines affects the uptake, resistance, and hesitancy to the COVID-19 vaccine. Information campaigns focusing on the efficacy and safety of vaccines could lead to improved acceptance of COVID-19 vaccines.

Identifiants

pubmed: 36709269
doi: 10.1186/s12889-023-15116-w
pii: 10.1186/s12889-023-15116-w
pmc: PMC9884132
doi:

Substances chimiques

COVID-19 Vaccines 0
Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

191

Informations de copyright

© 2023. The Author(s).

Références

Proc Natl Acad Sci U S A. 2021 Dec 7;118(49):
pubmed: 34795017
Int J Infect Dis. 2021 Mar;104:742-745
pubmed: 33556610
JAMA Netw Open. 2021 Aug 02;4(8):e2121931
pubmed: 34459907
J Health Commun. 2020 Oct 2;25(10):799-807
pubmed: 33719881
Vaccine. 2020 Jan 29;38(5):1160-1169
pubmed: 31791811
Risk Manag Healthc Policy. 2021 Jun 21;14:2609-2623
pubmed: 34188572
Niger Postgrad Med J. 2020 Oct-Dec;27(4):261-267
pubmed: 33154276
PLoS One. 2021 Sep 3;16(9):e0257109
pubmed: 34478470
Pediatr Nurs. 2005 Sep-Oct;31(5):380-6
pubmed: 16295153
Pan Afr Med J. 2021 Sep 03;40:10
pubmed: 34650660
BMC Public Health. 2021 Aug 18;21(1):1562
pubmed: 34404377
J Public Health (Oxf). 2018 Mar 1;40(1):121-128
pubmed: 28369548
Vaccines (Basel). 2021 Mar 12;9(3):
pubmed: 33809002
Brain Behav Immun. 2021 May;94:41-50
pubmed: 33713824
J Gen Intern Med. 2021 Jul;36(7):2130-2133
pubmed: 33754319
Am J Infect Control. 2022 Jan;50(1):20-25
pubmed: 34653527
Cureus. 2021 Sep 15;13(9):e17990
pubmed: 34667668
Euro Surveill. 2021 Dec;26(50):
pubmed: 34915975
Health Secur. 2021 Jan-Feb;19(1):44-56
pubmed: 33606572
EClinicalMedicine. 2020 Sep;26:100495
pubmed: 32838242
PLoS One. 2021 Apr 23;16(4):e0250555
pubmed: 33891660
J Relig Health. 2021 Feb;60(1):65-80
pubmed: 33125543
Vaccine. 2022 Jan 3;40(1):151-161
pubmed: 34863621
J Med Virol. 2022 Apr;94(4):1738-1744
pubmed: 34905235
JAMA. 2022 Feb 8;327(6):583-584
pubmed: 34967859
Vaccines (Basel). 2022 Feb 10;10(2):
pubmed: 35214724
Vaccine. 2022 Mar 8;40(11):1643-1654
pubmed: 33933316
J Med Internet Res. 2020 Apr 2;22(4):e18790
pubmed: 32240094
Hum Vaccin Immunother. 2021 May 4;17(5):1304-1312
pubmed: 33118868
BMJ Open. 2018 May 17;8(5):e021006
pubmed: 29773702
J Community Health. 2021 Apr;46(2):270-277
pubmed: 33389421
Lancet. 2021 Apr 3;397(10281):1265-1275
pubmed: 33773118
BMJ. 2021 May 20;373:n1138
pubmed: 34016653
PLoS One. 2021 Nov 29;16(11):e0260672
pubmed: 34843594
Vaccines (Basel). 2021 Sep 24;9(10):
pubmed: 34696172
Front Microbiol. 2020 Mar 17;11:372
pubmed: 32256465
Int J Health Plann Manage. 2021 Jul;36(4):1178-1188
pubmed: 33819370
Procedia Vaccinol. 2011;5:127-136
pubmed: 32288915
Int J MCH AIDS. 2021;10(1):134-138
pubmed: 33868778
Clin Infect Dis. 2022 Sep 14;75(5):893-896
pubmed: 35134167
Lancet Microbe. 2021 Jul;2(7):e279-e280
pubmed: 33899038
JAMA Netw Open. 2021 Sep 1;4(9):e2126882
pubmed: 34559232
PLoS One. 2021 Dec 1;16(12):e0260575
pubmed: 34851998
Biomed J. 2020 Aug;43(4):328-333
pubmed: 32387617
PLoS One. 2021 Dec 21;16(12):e0260731
pubmed: 34932583
Viruses. 2022 Jan 30;14(2):
pubmed: 35215887

Auteurs

Chundung Asabe Miner (CA)

Department of Community Medicine, College of Health Sciences, University of Jos, Jos, Plateau State, Nigeria.

Chikasirimobi G Timothy (CG)

Department of Optometry, Mzuzu University, Mzuzu, Malawi.
African Vision Research Institute (AVRI), School of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.

Uchechukwu Levi Osuagwu (UL)

African Vision Research Institute (AVRI), School of Health Sciences, University of KwaZulu-Natal, Durban, South Africa. l.osuagwu@westernsydney.edu.au.
Bathurst Rural Clinical School, School of Medicine, Western Sydney University, Bathurst, NSW, 2795, Australia. l.osuagwu@westernsydney.edu.au.
Translational Health Research Institute (THRI), Western Sydney University, 2506, New South Wales, Australia. l.osuagwu@westernsydney.edu.au.

Esther Awazzi Envuladu (EA)

Department of Community Medicine, College of Health Sciences, University of Jos, Jos, Nigeria.

Onyekachukwu Mary-Anne Amiebenomo (OM)

School of Optometry and Vision Sciences, College of Biomedical Sciences, Cardiff University, Cardiff, UK.
Department of Optometry, Faculty of Life Sciences, University of Benin, Benin City, Ugbowo, Nigeria.

Godwin Ovenseri-Ogbomo (G)

African Vision Research Institute (AVRI), School of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.
Department of Optometry, Centre for Health Sciences, University of the Highlands and Islands, Inverness, UK.

Deborah Donald Charwe (DD)

Tanzania Food and Nutrition Center, Dar-Es-Salaam, Tanzania.

Piwuna Christopher Goson (PC)

Department of Psychiatry, College of Health Sciences, University of Jos, Jos, Plateau State, Nigeria.

Bernadine N Ekpenyong (BN)

African Vision Research Institute (AVRI), School of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.
Department of Public Health, Faculty of Allied Medical Sciences, College of Medical Sciences, University of Calabar, Cross River State, Calabar, Nigeria.

Emmanuel Kwasi Abu (EK)

Department of Optometry and Vision Science, School of Allied Health Sciences, College of Health and Allied Sciences, University of Cape Coast, Cape Coast, Ghana.

Raymond Langsi (R)

Health Division, University of Bamenda, Bambili, Cameroon.

Richard Oloruntoba (R)

School of Management and Marketing, Curtin University, Kent Street, Bentley, WA, 6102, Australia.

Tanko Ishaya (T)

Department of Computer Science, University of Jos, Jos, Nigeria.

Kingsley E Agho (KE)

African Vision Research Institute (AVRI), School of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.
Translational Health Research Institute (THRI), Western Sydney University, 2506, New South Wales, Australia.
School of Health Science, Western Sydney University, Campbelltown, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH